Læknablaðið - 01.02.1974, Síða 89

LÆKNABLAÐIÐ
51
23. Miettinen, M., Turpeinen, O., Karvonen,
M. J., Elosuo, R. & Paaviliainen, E. Effect
of cholesterol lowering diet on mortality
from coronary heart disease and other
causes. A twelve-year clinical trial in men
and women. Lancet 2:835. 1972.
24. Myant, N. B. & Slack, J. Type II hyper-
lipoproteinaemia. Glinics in Endocrinology
and Metábolism, 2, I, p. 94. 1973. .
25. Pinkney, E. R. The potential toxicity of
excessive polyunsaturates. Amer. Heart J.
85:723. 1973.
26. Rifkind, B. M. (Editor) Disorders of Lipid
Metabolism. Clinics in Endocrinology and
Metabolism Vol. 2, No. I. 1973.
27. Schrimshaw, N. S., Guzman, M. A. Geo-
graphic pathology of atherosclerosis. Die't
and atheroselerosis. Lab. Invest. 18:623.
1968.
28. Slack, J. Risks of ischaemic heart disease
in familial hyperlipoproteinaemic states.
Lancet 2:1380. 1969.
29. Smellie, R. M. S. (Editor) Plasma Lipo-
proteins. Academic Press. 1971.
30. Stamler, J. in The Pathogenesis of Atheros-
clerosis, p. 55. The Williams and Wilkins
Company, Baltimore 1972.
31. Stokes, T. & Wynn, V. Serum lipids in
women on oral contraceptives. Lancet
2:677. 1971.
32. Zelis, R., Mason, D. T., Braunwald, E. &
Levy, R. I. Effects of hyperlipoprotein-
aemias and their treatment on the peri-
pheral circulation. J. Clin. Invest. 49:1007.
1970.